Early Illness Features Associated with Mortality in the Juvenile Idiopathic Inflammatory Myopathies

Overview

Journal Arthritis Care Res (Hoboken)

Specialty Rheumatology

Date 2013 Oct 24

PMID 24151254

Citations 37

Authors

Adam M Huber

Gulnara Mamyrova

Peter A Lachenbruch

Julia A Lee

James D Katz

Ira N Targoff

Frederick W Miller

Lisa G Rider

Affiliations

Soon will be listed here.

Abstract

Objective: Because juvenile idiopathic inflammatory myopathies (IIMs) are potentially life-threatening systemic autoimmune diseases, we examined risk factors for juvenile IIM mortality.

Methods: Mortality status was available for 405 patients (329 with juvenile dermatomyositis [DM], 30 with juvenile polymyositis [PM], and 46 with juvenile connective tissue disease-associated myositis [CTM]) enrolled in nationwide protocols. Standardized mortality ratios (SMRs) were calculated using US population statistics. Cox regression analysis was used to assess univariable associations with mortality, and random survival forest (RSF) classification and Cox regression analysis were used for multivariable associations.

Results: Of 17 deaths (4.2% overall mortality), 8 (2.4%) were in juvenile DM patients. Death was related to the pulmonary system (primarily interstitial lung disease [ILD]) in 7 patients, gastrointestinal system in 3, and multisystem in 3, and of unknown etiology in 4 patients. The SMR for juvenile IIMs overall was 14.4 (95% confidence interval [95% CI] 12.2-16.5) and was 8.3 (95% CI 6.4-10.3) for juvenile DM. The top mortality risk factors in the univariable analysis included clinical subgroup (juvenile CTM, juvenile PM), antisynthetase autoantibodies, older age at diagnosis, ILD, and Raynaud's phenomenon at diagnosis. In multivariable analyses, clinical subgroup, illness severity at onset, age at diagnosis, weight loss, and delay to diagnosis were the most important predictors from RSF; clinical subgroup and illness severity at onset were confirmed by multivariable Cox regression analysis.

Conclusion: Overall mortality was higher in juvenile IIM patients, and several early illness features were identified as risk factors. Clinical subgroup, antisynthetase autoantibodies, older age at diagnosis, and ILD are also recognized as mortality risk factors in adult myositis.

Citing Articles

Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.

Kobayashi I Children (Basel). 2024; 11(9).

PMID: 39334579 PMC: 11430821. DOI: 10.3390/children11091046.

Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality.

Sherman M, Noroozi Farhadi P, Pak K, Trieu E, Sarkar K, Targoff I Arthritis Rheumatol. 2024; 76(6):963-972.

PMID: 38272842 PMC: 11136598. DOI: 10.1002/art.42813.

Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor.

Zhang H, Yue J, Hou X, Lu H, Bikdeli A, Guo H BMC Pulm Med. 2023; 23(1):248.

PMID: 37415133 PMC: 10326956. DOI: 10.1186/s12890-023-02542-0.

Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.

Papadopoulou C, Chew C, Wilkinson M, McCann L, Wedderburn L Nat Rev Rheumatol. 2023; 19(6):343-362.

PMID: 37188756 PMC: 10184643. DOI: 10.1038/s41584-023-00967-9.

Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.

Sherman M, Graf R, Sabbagh S, Galindo-Feria A, Pinal-Fernandez I, Pak K Rheumatology (Oxford). 2022; 62(SI2):SI226-SI234.

PMID: 35961028 PMC: 9949705. DOI: 10.1093/rheumatology/keac428.

References

Marie I, Hatron P, Dominique S, Cherin P, Mouthon L, Menard J . Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2011; 41(6):890-9. DOI: 10.1016/j.semarthrit.2011.09.008. View

Hashkes P, Wright B, Lauer M, Worley S, Tang A, Roettcher P . Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010; 62(2):599-608. DOI: 10.1002/art.27218. View

Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G . Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004; 83(1):35-42. DOI: 10.1097/01.md.0000109755.65914.5e. View

Bronner I, van der Meulen M, de Visser M, Kalmijn S, van Venrooij W, Voskuyl A . Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006; 65(11):1456-61. PMC: 1798355. DOI: 10.1136/ard.2005.045690. View

Kuo C, See L, Yu K, Chou I, Chang H, Chiou M . Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011; 165(6):1273-9. DOI: 10.1111/j.1365-2133.2011.10595.x. View

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

Rider L, Shah M, Mamyrova G, Huber A, Rice M, Targoff I . The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013; 92(4):223-243. PMC: 3721421. DOI: 10.1097/MD.0b013e31829d08f9. View

Love L, Leff R, Fraser D, Targoff I, Dalakas M, Plotz P . A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991; 70(6):360-74. DOI: 10.1097/00005792-199111000-00002. View

Lundberg I, Forbess C . Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2008; 26(5 Suppl 51):S109-14. View

10.

Torres C, Belmonte R, Carmona L, Gomez-Reino F, Galindo M, Ramos B . Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006; 39(3):205-15. DOI: 10.1080/08916930600622603. View

11.

BITNUM S, DAESCHNER Jr C, Travis L, Dodge W, HOPPS H . DERMATOMYOSITIS. J Pediatr. 1964; 64:101-31. DOI: 10.1016/s0022-3476(64)80325-5. View

12.

Huber A . Idiopathic inflammatory myopathies in childhood: current concepts. Pediatr Clin North Am. 2012; 59(2):365-80. DOI: 10.1016/j.pcl.2012.03.006. View

13.

Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N . Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011; 29(1):117-24. View

14.

Arias E, Curtin L, Wei R, Anderson R . U.S. decennial life tables for 1999-2001, United States life tables. Natl Vital Stat Rep. 2008; 57(1):1-36. View

15.

Feldman B, Rider L, Reed A, Pachman L . Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008; 371(9631):2201-12. DOI: 10.1016/S0140-6736(08)60955-1. View

16.

Cox F, Titulaer M, Sont J, Wintzen A, Verschuuren J, Badrising U . A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011; 134(Pt 11):3167-75. DOI: 10.1093/brain/awr217. View

17.

Ward M, Pajevic S, Dreyfuss J, Malley J . Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum. 2006; 55(1):74-80. DOI: 10.1002/art.21695. View

18.

Airio A, Kautiainen H, Hakala M . Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006; 25(2):234-9. DOI: 10.1007/s10067-005-1164-z. View

19.

Limaye V, Hakendorf P, Woodman R, Blumbergs P, Roberts-Thomson P . Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J. 2010; 42(2):191-8. DOI: 10.1111/j.1445-5994.2010.02406.x. View

20.

McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K . The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-60. DOI: 10.1093/rheumatology/kel099. View